CGX Chromogenex

RNS Number:8915Y
Chromogenex PLC
25 June 2007



                                Chromogenex plc

                               New Product Launch

An advanced system designed to help people stop smoking has been launched by
AIM-listed medical and aesthetic laser device company Chromogenex. With the UK's
smoking in public places ban coming into effect on 1 July 2007, the Nicolite
laser has been introduced to meet the anticipated demand for such aids.

Nicolite is a laser system which uses a coherent beam of light of low power to
stimulate the release of endorphins by the body. Endorphins are the body's
natural painkillers and research suggests that endorphins also help to suppress
physical cravings such as the desire for nicotine.

Products to assist smoking cessation is a multi million pound market and reports
suggest that with the UK's new mandatory ban on smoking in public places the
demand for smoking cessation treatments will rise rapidly.

Peter McGuinness, Chairman of Chromogenex, commented: 'Our Nicolite system will
be rolled out over the forthcoming months into the 1200 plus clinics registered
to provide laser treatment in the UK. As well as servicing this rapidly growing
market we also plan to sell the product internationally through our existing
distribution network.'

                                    - ends -

For further information:
Chromogenex plc                                                   020 8434 0540
Peter McGuinness, Chairman                                        07775 834 777

Blue Oar                                                          020 7448 4400
Jerry Keen

Threadneedle Communications                                       020 7936 9605
Graham Herring/Josh Royston                                       07793 839 024


Notes to Editors:
Chromogenex plc is a profitable and established medical and aesthetic laser
device company that joined AIM, part of the London Stock Exchange in June 2005.

Its principal products include:

   *The Chromolite(TM), a safe and effective intense pulsed light device for
    treating unwanted hair, skin pigmentation and thread vein removal. The
    Chromolite received FDA-approval in January 2006 to distribute its products
    in the US.


   *The NLite(TM)-V, a patented pulsed-dye laser system initially developed to
    treat vascular lesions, but proven it to be equally effective in treating
    Acne Vulgaris (the world's commonest skin disease), psoriasis, which affects
    3% of the population and also skin rejuvenation by rebuilding collagen in
    the skin.


   *Smoothshapes(R) 100 is a painless, non-invasive laser-based system that
    works gradually and effectively to improve the appearance of cellulite.


   *Nicolite is a laser system targeting smoking cessation which uses a
    coherent beam of light of low power to stimulate the release of endorphins
    by the body.


Chromogenex's products are technically advanced and are well protected by
sufficient patent protection. The current range is clinically proven and
conforms to the most stringent medical standards. Its products are also
supported by world-leading luminaries in dermatology, including Dr Tony Chu, a
leading UK authority on acne. In October 2003, Dr Chu published positive results
of his clinical trials in the Lancet proving the efficacy of NLite(TM)-V for the
treatment of Acne Vulgaris.

The global cosmetic surgery market is worth $20bn according to the American
Society for Aesthetic Plastic Surgery. In addition, CIBC World Markets states
that the cosmetic laser market is valued at about $1bn worldwide, with sales
having grown by 15% last year. Chromogenex is well positioned to exploit this
massive and ever increasing area.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
PRLEASKAADDXEFE

Chromogenex (LSE:CGX)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Chromogenex (LSE:CGX)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025